Eisai Co., Ltd. has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide for EZH2 gene mutation-positive follicular lymphoma.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest